

Logon

*** It is now 6/8/08 2:21:44 PM ***

Welcome to DialogLink - Version 5 Revolutionize the Way You Work!

New on Dialog

Order Patent and Trademark File Histories Through Dialog

Thomson File Histories are now available directly through *Dialog*. Combined with the comprehensive patent and trademark information on *Dialog*, file histories give you the most complete view of a patent or trademark and its history in one place. When searching in the following patent and trademark databases, a link to an online order form is displayed in your search results, saving you time in obtaining the file histories you need.

Thomson File Histories are available from the following *Dialog* databases:

- CLAIMS/Current Patent Legal Status (File 123)
- CLAIMS/U.S. Patents (File 340)
- Chinese Patent Abstracts in English (File 344)
- Derwent Patents Citation Index (File 342)
- Derwent World Patents Index (for users in Japan) (File 352)
- Derwent World Patents Index First View (File 331)
- Derwent World Patents Index (File 351)
- Derwent World Patents Index (File 350)
- Ei EnCompassPat (File 353)
- European Patents Fulltext (File 348)
- French Patents (File 371)
- German Patents Fulltext (File 324)
- IMS Patent Focus (File 447, 947)
- INPADOC/Family and Legal Status (File 345)
- JAPIO - Patent Abstracts of Japan (File 347)
- LitAlert (File 670)
- U.S. Patents Fulltext (1971-1975) (File 652)

- U.S. Patents Fulltext (1976-present) (File 654)
- WIPO/PCT Patents Fulltext (File 349)
- TRADEMARKSCAN - U.S. Federal (File 226)

DialogLink 5 Release Notes

New features available in the latest release of DialogLink 5 (August 2006)

- Ability to resize images for easier incorporation into DialogLink Reports
- New settings allow users to be prompted to save Dialog search sessions in the format of their choice (Microsoft Word, RTF, PDF, HTML, or TEXT)
- Ability to set up Dialog Alerts by Chemical Structures and the addition of Index Chemicus as a structure searchable database
- Support for connections to STN Germany and STN Japan services

Show Preferences for details

? Help Log On Msg

*** ANNOUNCEMENTS ***

"Thomson File Histories" are now available directly through Dialog in selected patent and trademark files. Combined with the comprehensive patent and trademark information on Dialog, file histories give you the most complete view of a patent or trademark and its history in one place. When searching in one of the patent and trademark databases, a link to an online order form is displayed in your search results, saving you time in obtaining the file histories you need. See HELP FILEHIST for more information about how to use the link and a list of files that contain the link.

The 2008 EMTREE Thesaurus has been added to EMBASE (Files 72, 73, 772, and 972)

RESUMED UPDATING

***File 120, U.S. Copyrights

RELOADS COMPLETED

***File 156, ToxFile (annual reload)

FILES REMOVED

***Files 476/Financial Times & 473/Financial Times Abstracts

***Files 359,959,804, Chemical Economics Handbook

***Files 360,960, Specialty Chemicals Update Program

>>>For the latest news about Dialog products, services, content<<<

>>>and events, please visit What's New from Dialog at <<<

>>><http://www.dialog.com/whatsnew/>. You can find news about <<<

>>>a specific database by entering HELP NEWS <file number>. <<<

? Help Off Line

* * *

Connecting to Suzanne Noakes - Dialog - 276629

Connected to Dialog via SMS00304537

? b 155 biosci medicine 399

>>>W: 44 is unauthorized

76 is unauthorized

138 is unauthorized

3 of the specified files are not available

[File 155] MEDLINE(R) 1950-2008/Jun 09

(c) format only 2008 Dialog. All rights reserved.

*File 155: MEDLINE has reloaded. Please see HELP NEWS 155 for details.

[File 5] Biosis Previews(R) 1926-2008/Jun W1

(c) 2008 The Thomson Corporation. All rights reserved.

[File 24] CSA Life Sciences Abstracts 1966-2008/Mar

(c) 2008 CSA. All rights reserved.

[File 28] Oceanic Abstracts 1966-2008/Jun

(c) 2008 CSA. All rights reserved.

[File 34] SciSearch(R) Cited Ref Sci 1990-2008/Jun W2

(c) 2008 The Thomson Corp. All rights reserved.

[File 35] Dissertation Abs Online 1861-2008/Nov
(c) 2008 ProQuest Info&Learning. All rights reserved.

[File 40] Environline(R) 1975-2008/Apr
(c) 2008 Congressional Information Service. All rights reserved.

[File 41] Pollution Abstracts 1966-2008/May
(c) 2008 CSA. All rights reserved.

[File 45] EMCare 2008/May W4
(c) 2008 Elsevier B.V. All rights reserved.

[File 50] CAB Abstracts 1972-2008/Apr
(c) 2008 CAB International. All rights reserved.

[File 65] Inside Conferences 1993-2008/Jun 06
(c) 2008 BLDSC all rts. reserv. All rights reserved.

[File 71] ELSEVIER BIOBASE 1994-2008/May W3
(c) 2008 Elsevier B.V. All rights reserved.

[File 73] EMBASE 1974-2008/Jun 04
(c) 2008 Elsevier B.V. All rights reserved.

**File 73: The 2008 EMTREE Thesaurus has been loaded. Please see HELP NEWS 72 for details.*

[File 91] MANTIS(TM) 1880-2008/Aug
2001 (c) Action Potential. All rights reserved.

[File 98] General Sci Abs 1984-2008/May
(c) 2008 The HW Wilson Co. All rights reserved.

[File 110] WasteInfo 1974-2002/Jul
(c) 2002 AEA Techn Env. All rights reserved.

**File 110: This file is closed (no updates)*

[File 135] NewsRx Weekly Reports 1995-2008/Jun W1
(c) 2008 NewsRx. All rights reserved.

[File 136] BioEngineering Abstracts 1966-2007/Jan
(c) 2007 CSA. All rights reserved.

**File 136: This file is closed.*

[File 143] Biol. & Agric. Index 1983-2008/Apr
(c) 2008 The HW Wilson Co. All rights reserved.

[File 144] Pascal 1973-2008/May W4
(c) 2008 INIST/CNRS. All rights reserved.

[File 164] Allied & Complementary Medicine 1984-2008/Jun
(c) 2008 BLHCIS. All rights reserved.

[File 172] EMBASE Alert 2008/Jun 05
(c) 2008 Elsevier B.V. All rights reserved.

[File 185] Zoological Record Online(R) 1864-2008/Jun
(c) 2008 The Thomson Corp. All rights reserved.

**File 185: The file has been reloaded to add archive records back to 1864. Accession numbers have changed.*

[File 357] Derwent Biotech Res. _1982-2008/May W2
(c) 2008 The Thomson Corp. All rights reserved.

[File 369] New Scientist 1994-2008/Feb W4
(c) 2008 Reed Business Information Ltd. All rights reserved.

[File 370] Science 1996-1999/Jul W3
(c) 1999 AAAS. All rights reserved.

**File 370: This file is closed (no updates). Use File 47 for more current information.*

[File 391] Beilstein Database - Reactions 2007/Q4
(c) 2008 Beilstein GmbH. All rights reserved.

[File 434] SciSearch(R) Cited Ref Sci 1974-1989/Dec
(c) 2006 The Thomson Corp. All rights reserved.

[File 467] ExtraMED(tm) 2000/Dec
(c) 2001 Informania Ltd. All rights reserved.

[File 149] TGG Health&Wellness DB(SM) 1976-2008/May W4
(c) 2008 The Gale Group. All rights reserved.

[File 156] ToxFile 1965-2008/Jun W1
(c) format only 2008 Dialog. All rights reserved.

**File 156: ToxFile has been reloaded. Accession numbers have changed.*

[File 159] Cancerlit 1975-2002/Oct
(c) format only 2002 Dialog. All rights reserved.

[File 162] Global Health 1983-2008/Apr
(c) 2008 CAB International. All rights reserved.

[File 266] FEDRIP 2008/Feb
Comp & dist by NTIS, Intl Copyright All Rights Res. All rights reserved.

[File 399] CA SEARCH(R) 1967-2008/UD=14823
(c) 2008 American Chemical Society. All rights reserved.

**File 399: Use is subject to the terms of your user/customer agreement. IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.*

[File 444] New England Journal of Med. 1985-2008/Mar W3
(c) 2008 Mass. Med. Soc. All rights reserved.

? s (cetuximab or erbitux or MabC225 or IMC-C225) (N50) (crystal? or co-crystal? or cocrystal?)

Processing

10785 CETUXIMAB

3330 ERBITUX

4 MABC225

83 IMC-C225
4187178 CRYSTAL?
592 CO-CRYSTAL?
8935 COCRYSTAL?
S1 69 S (CETUXIMAB OR ERBITUX OR MABC225 OR IMC-C225) (N50) (CRYSTAL? OR CO-CRYSTAL? OR COCRYSTAL?)

? rd
>>>W: Duplicate detection is not supported for File 391.
Records from unsupported files will be retained in the RD set.
S2 39 RD (UNIQUE ITEMS)

? s s2 and PY<=2003
Processing
>>>W: One or more prefixes are unsupported
or undefined in one or more files.

39 S2
129165365 PY<=2003
S3 0 S S2 AND PY<=2003

? t s2/ti/all
>>>W: No matching display code(s) found in file(s):
2/TI/1 (Item 1 from file: 155)
MEDLINE(R)
(c) format only 2008 Dialog. All rights reserved.
Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.

2/TI/2 (Item 2 from file: 155)

MEDLINE(R)

(c) format only 2008 Dialog. All rights reserved.

Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.

2/TI/3 (Item 3 from file: 155)

MEDLINE(R)

(c) format only 2008 Dialog. All rights reserved.

Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8.

2/TI/4 (Item 4 from file: 155)

MEDLINE(R)

(c) format only 2008 Dialog. All rights reserved.

Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment.

2/TI/5 (Item 5 from file: 155)

MEDLINE(R)

(c) format only 2008 Dialog. All rights reserved.

First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.

2/TI/6 (Item 6 from file: 155)

MEDLINE(R)

(c) format only 2008 Dialog. All rights reserved.

Targeted agents to improve treatment results in colon cancer: bevacizumab and cetuximab.

2/TI/7 (Item 7 from file: 155)

MEDLINE(R)

(c) format only 2008 Dialog. All rights reserved.

[Cetuximab]

2/TI/8 (Item 8 from file: 155)

MEDLINE(R)

(c) format only 2008 Dialog. All rights reserved.

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.

2/TI/9 (Item 9 from file: 155)

MEDLINE(R)

(c) format only 2008 Dialog. All rights reserved.

EGF receptor inhibition: attacks on multiple fronts.

2/TI/10 (Item 1 from file: 5)

Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rights reserved.

CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC)

2/TI/11 (Item 1 from file: 34)

SciSearch(R) Cited Ref Sci

(c) 2008 The Thomson Corp. All rights reserved.

Cetuximab plus folfiri first-line in metastatic colorectal cancer (MCRC): The randomized phase III crystal trial

2/TI/12 (Item 2 from file: 34)

SciSearch(R) Cited Ref Sci

(c) 2008 The Thomson Corp. All rights reserved.

Cetuximab with irinotecan in first-line treatment of epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): Preliminary safety results (CRYSTAL).

2/TI/13 (Item 1 from file: 73)

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

Cetuximab cuts progression risk by 15% in CRYSTAL trial: Commentary

2/TI/14 (Item 2 from file: 73)

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer

2/TI/15 (Item 1 from file: 135)

NewsRx Weekly Reports

(c) 2008 NewsRx. All rights reserved.

Researchers from University of Pennsylvania, Department of Physiology provide details of new studies and findings in the area of monoclonal antibodies

2/TI/16 (Item 2 from file: 135)

NewsRx Weekly Reports

(c) 2008 NewsRx. All rights reserved.

Studies from University of Pennsylvania, Department of Physiology describe new findings in life sciences

2/TI/17 (Item 3 from file: 135)

NewsRx Weekly Reports

(c) 2008 NewsRx. All rights reserved.

Study data from University Francois Rabelais of Tours provide new insights into monoclonal antibodies

2/TI/18 (Item 4 from file: 135)

NewsRx Weekly Reports

(c) 2008 NewsRx. All rights reserved.

Yale University details research in colon cancer

2/TI/19 (Item 5 from file: 135)

NewsRx Weekly Reports

(c) 2008 NewsRx. All rights reserved.

Merck KgaA reports Erbitux meets primary endpoint in metastatic colorectal cancer study

2/TI/20 (Item 6 from file: 135)

NewsRx Weekly Reports

(c) 2008 NewsRx. All rights reserved.

Merck KgaA reports survival data from Erbitux studies in metastatic colorectal cancer

2/TI/21 (Item 7 from file: 135)

NewsRx Weekly Reports

(c) 2008 NewsRx. All rights reserved.

Merck KGaA releases new Erbitux data

2/TI/22 (Item 8 from file: 135)

NewsRx Weekly Reports

(c) 2008 NewsRx. All rights reserved.

Clinical data suggest Erbitux recruits immune system to help fight cancer

2/TI/23 (Item 9 from file: 135)
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

ImClone completes enrollment in studies of Erbitux in three cancer types

2/TI/24 (Item 10 from file: 135)
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

Researchers determine structure of binding site of drug and its protein target

2/TI/25 (Item 11 from file: 135)
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

Pharma company announces financial results with tripled profit after tax gains

2/TI/26 (Item 12 from file: 135)
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

Pharma company announces profit increase of 43%

2/TI/27 (Item 13 from file: 135)

NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

Pharmaceutical company announces second quarter financial results

2/TI/28 (Item 1 from file: 144)
Pascal
(c) 2008 INIST/CNRS. All rights reserved.

Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment : Antibodies in cancer treatment-II

2/TI/29 (Item 1 from file: 357)
Derwent Biotech Res.
(c) 2008 The Thomson Corp. All rights reserved.
New crystal of epidermal growth factor receptor extracellular domain and cetuximab Fab, useful for treating tumor or hyperproliferative disease, e.g. psoriasis using bioinformatics for crystal protein structure analysis for use in cancer therapy

2/TI/30 (Item 1 from file: 149)
TGG Health&Wellness DB(SM)
(c) 2008 The Gale Group. All rights reserved.
New Analyses of Pivotal Phase 3 Study of ERBITUX(R) Demonstrate Enhanced Efficacy in First-Line Metastatic Colorectal Cancer Patients with Wild-Type K-Ras Biomarker.

2/TI/31 (Item 2 from file: 149)
TGG Health&Wellness DB(SM)
(c) 2008 The Gale Group. All rights reserved.
Targeted therapies: a new generation of cancer treatments.(Clinical report)

2/TI/32 (Item 3 from file: 149)

TGG Health&Wellness DB(SM)

(c) 2008 The Gale Group. All rights reserved.

Structural Basis for EGF Receptor Inhibition by the Therapeutic Antibody IMC-11F8.(Author abstract)(Report)

2/TI/33 (Item 4 from file: 149)

TGG Health&Wellness DB(SM)

(c) 2008 The Gale Group. All rights reserved.

Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting.

2/TI/34 (Item 5 from file: 149)

TGG Health&Wellness DB(SM)

(c) 2008 The Gale Group. All rights reserved.

ImClone Systems to Host Investor Reception on June 5, 2007 Following a Clinical Science Symposium Session about EGFR as a Therapeutic Target in GI Malignancy.

2/TI/35 (Item 6 from file: 149)

TGG Health&Wellness DB(SM)

(c) 2008 The Gale Group. All rights reserved.

ImClone Systems Announces Complete Enrollment of Several Studies Examining Potential Survival Benefit Of ERBITUX(R) In Three Major Cancer Types.

2/TI/36 (Item 1 from file: 266)

FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rights reserved.

Structural Studies of Growth Factor Receptor Function

2/TI/37 (Item 1 from file: 399)

CA SEARCH(R)

(c) 2008 American Chemical Society. All rights reserved.

Co-crystal structure of epidermal growth factor receptor extracellular domain and cetuximab Fab fragment its use in screening for mimetics for treatment of tumors and psoriasis

2/TI/38 (Item 1 from file: 444)
New England Journal of Med.
(c) 2008 Mass. Med. Soc. All rights reserved.

Drug Therapy: EGFR Antagonists in Cancer Treatment (Review Article)

2/TI/39 (Item 2 from file: 444)
New England Journal of Med.
(c) 2008 Mass. Med. Soc. All rights reserved.

Cetuximab for the Treatment of Colorectal Cancer (Original Articles)

? d s

Set	Items	Description
S1	69	S (CETUXIMAB OR ERBITUX OR MABC225 OR IMC-C225) (N50) (CRYSTAL? OR CO-CRYSTAL? OR COCRYSTAL?)
S2	39	RD (unique items)
S3	0	S S2 AND PY<=2003

? s s2 and py<=2003

Processing

Processing

Processing

Processing

Processing

Processing

Processing

>>>W: One or more prefixes are unsupported
or undefined in one or more files.

39 S2

129165365 PY<=2003

S4

0 S S2 AND PY<=2003

? t s2/medium/all

2/3/1 (Item 1 from file: 155)

Fulltext available through: [STIC Full Text Retrieval Options](#)
MEDLINE(R)

(c) format only 2008 Dialog. All rights reserved.

26662804 PMID: 18503402

Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.

Jean Gary W; Shah Sachin R

1 School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, Texas.

Pharmacotherapy (United States) Jun 2008 , 28 (6) p742-54 , ISSN: 0277-0008--Print Journal Code: 8111305
Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: In Data Review

2/3/2 (Item 2 from file: 155)

Fulltext available through: [STIC Full Text Retrieval Options](#)
MEDLINE(R)

(c) format only 2008 Dialog. All rights reserved.

26471579 PMID: 18394559

Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.

Schmiedel Judith; Blaukat Andree; Li Shiqing; Knochel Thorsten; Ferguson Kathryn M

Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.

Cancer cell (United States) Apr 2008 , 13 (4) p365-73 , ISSN: 1535-6108--Print Journal Code: 101130617
Contract/Grant No.: R01-CA112552; CA; United States NCI

Publishing Model Print; Comment in Cancer Cell. 2008 Apr;13(4) 291-3; Comment in PMID 18394550

Document type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't;
Research Support, U.S. Gov't, Non-P.H.S.

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

2/3/3 (Item 3 from file: 155)

Fulltext available through: [STIC Full Text Retrieval Options](#)
MEDLINE(R)

(c) format only 2008 Dialog. All rights reserved.

26405056 PMID: 18275813

Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8.

Li Shiqing; Kussie Paul; Ferguson Kathryn M
Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Structure (London, England - 1993) (United States) Feb 2008 , 16 (2) p216-27 , ISSN: 0969-2126--Print
Journal Code: 101087697
Contract/Grant No.: R01-CA112552; CA; United States NCI
Publishing Model Print
Document type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't;
Research Support, U.S. Gov't, Non-P.H.S.
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

2/3/4 (Item 4 from file: 155)

Fulltext available through: [STIC Full Text Retrieval Options](#)
MEDLINE(R)

(c) format only 2008 Dialog. All rights reserved.

25886201 PMID: 17624800

Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment.

Magdelaine-Beuzelin Charlotte; Kaas Quentin; Wehbi Vanessa; Ohresser Marc; Jefferis Roy; Lefranc Marie-Paule;
Watier Herve

Universite Francois Rabelais de Tours, EA 3853 Immuno-Pharmaco-Genetique des Anticorps therapeutiques,
France.

Critical reviews in oncology/hematology (Ireland) Dec 2007 , 64 (3) p210-25 , ISSN: 1040-8428--Print

Journal Code: 8916049

Publishing Model Print-Electronic; Comment in Crit Rev Oncol Hematol. 2007 Dec;64(3) 208-9; Comment in
PMID 17986426

Document type: Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Review

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

2/3/5 (Item 5 from file: 155)

Fulltext available through: [STIC Full Text Retrieval Options](#)
MEDLINE(R)

(c) format only 2008 Dialog. All rights reserved.

25633377 PMID: 18021486

First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.

Lee James J; Chu Edward

Section of Medical Oncology, Developmental Therapeutics Program, Yale Cancer Center, Yale University School of
Medicine, New Haven, CT 06520, USA. james.j.lee@yale.edu

Clinical colorectal cancer (United States) Oct 2007 , 6 Suppl 2 pS42-6 , ISSN: 1533-0028--Print Journal
Code: 101120693
Publishing Model Print
Document type: Journal Article; Review
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

2/3/6 (Item 6 from file: 155)

Fulltext available through: [STIC Full Text Retrieval Options](#)
MEDLINE(R)
(c) format only 2008 Dialog. All rights reserved.
25074496 PMID: 17935270

Targeted agents to improve treatment results in colon cancer: bevacizumab and cetuximab.

Klein Baruch; Gottfried Maya
Institute of Oncology, Meir Medical Center, Kfar Saba, Israel. Baruch.Klein@clalit.org.il
Journal of B.U.ON. - official journal of the Balkan Union of Oncology (Greece) Sep 2007 , 12 Suppl 1 pS127-36
, ISSN: 1107-0625--Print Journal Code: 100883428
Publishing Model Print
Document type: Journal Article; Review
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

2/3/7 (Item 7 from file: 155)

Fulltext available through: [STIC Full Text Retrieval Options](#)
MEDLINE(R)
(c) format only 2008 Dialog. All rights reserved.
17816959 PMID: 17687200
[Cetuximab]

Takiuchi Hiroya
Cancer Chemotherapy Center, Osaka Medical College Hospital, Japan.
Gan to kagaku ryoho. Cancer & chemotherapy (Japan) Aug 2007 , 34 (8) p1192-5 , ISSN: 0385-0684--Print
Journal Code: 7810034
Publishing Model Print
Document type: English Abstract; Journal Article; Review
Languages: JAPANESE
Main Citation Owner: NLM
Record type: MEDLINE; Completed

2/3/8 (Item 8 from file: 155)

Fulltext available through: [STIC Full Text Retrieval Options](#)

MEDLINE(R)

(c) format only 2008 Dialog. All rights reserved.

16342169 PMID: 15837620

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.

Li Shiqing; Schmitz Karl R; Jeffrey Philip D; Wiltzius Jed J W; Kussie Paul ; Ferguson Kathryn M

Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.

Cancer cell (United States) Apr 2005 , 7 (4) p301-11 , ISSN: 1535-6108--Print Journal Code: 101130617

Contract/Grant No.: K01-CA092246; CA; United States NCI; RR-01646; RR; United States NCRR; T32-HL007027; HL; United States NHLBI

Publishing Model Print

Document type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

2/3/9 (Item 9 from file: 155)

Fulltext available through: [STIC Full Text Retrieval Options](#)

MEDLINE(R)

(c) format only 2008 Dialog. All rights reserved.

16342164 PMID: 15837615

EGF receptor inhibition: attacks on multiple fronts.

Hubbard Stevan R

Structural Biology Program, Skirball Institute of Biomolecular Medicine, New York University School of Medicine, New York, New York 10016, USA. hubbard@saturn.med.nyu.edu <hubbard@saturn.med.nyu.edu>

Cancer cell (United States) Apr 2005 , 7 (4) p287-8 , ISSN: 1535-6108--Print Journal Code: 101130617

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

2/3/10 (Item 1 from file: 5)

Fulltext available through: [STIC Full Text Retrieval Options](#)

Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rights reserved.

0020082656 Biosis No.: 200800129595

CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC)

Author: Van Cutsem E (Reprint); Bodoky G; Kyung Roh J; Folprecht G; Park Y S; Van Laethem J L; Raoul J L; Ciardiello F; Lebrun P; Rougier P

Author Address: Univ Hosp Gasthuisberg, Dept Gastroenterol, B-3000 Louvain, Belgium** Belgium

Journal: EJC Supplements 5 (4): p 235 SEP 2007 2007
Conference/Meeting: 14th European Cancer Conference (ECCO 14) Barcelona, SPAIN September 23 -27, 2007;
20070923
Sponsor: European Canc Org
ISSN: 1359-6349
Document Type: Meeting; Meeting Abstract
Record Type: Citation
Language: English

2/3/11 (Item 1 from file: 34)

Fulltext available through: [STIC Full Text Retrieval Options](#)
SciSearch(R) Cited Ref Sci
(c) 2008 The Thomson Corp. All rights reserved.
16846624 Genuine Article#: 207WC No. References: 0
Cetuximab plus folfiri first-line in metastatic colorectal cancer (MCRC): The randomized phase III crystal trial

Author: Koehne C; Zaluski J; Chung RC; Makhson A; D'Haens G; Pinter T; Lim R; Ruff P; Rougier P; Van Cutsem E

Corporate Source: Klinikum Oldenburg,Oldenburg//Germany/; Oddzial Chemioterapii,Wielkopolskie Ctr Onkol,Poznan//Poland/; Dept Proctol Surg,Tao Yuan//Taiwan/; MOscow City Oncol Clin Hosp,Moscow//Russia/; Imelda Ziekenhuis,Bonheiden//Belgium/; Natl Univ Singapore Hosp,Singapore//Singapore/; Univ Witwatersrand,Johannesburg//South Africa/; Hop Ambroise Pare,Boulogne//France/; Univ Hosp Gasthuisberg,B-3000 Louvain//Belgium/

Journal: ANNALS OF ONCOLOGY , 2007 , V 18 , 7 , P VII21-VII21

ISSN: 0923-7534 Publication date: 20070000

Publisher: OXFORD UNIV PRESS , GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND

Language: English Document Type: MEETING ABSTRACT

2/3/12 (Item 2 from file: 34)

Fulltext available through: [STIC Full Text Retrieval Options](#)
SciSearch(R) Cited Ref Sci
(c) 2008 The Thomson Corp. All rights reserved.
15776046 Genuine Article#: 063HN No. References: 0
Cetuximab with irinotecan in first-line treatment of epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): Preliminary safety results (CRYSTAL).

Author: Lang I; Zaluski J; Changchien CR; Makhson A; Pinter T; D'Haens G; Lim R; Nippgen J; Van Cutsem E
Corporate Source: Orszagos Onkol Intezet,Budapest//Hungary/; Wielkopolskie Ctr Onkol,Poznan//Poland/; Chang Gung Mem Hosp,Tao Yuan//Taiwan/; Moscow City Oncol Clin Hosp,Moscow//Russia/; Cty Teaching Hosp,Gyor//Hungary/; Imelda Ziekenhuis,Bonheiden//Belgium/; Natl Univ Singapore Hosp,Singapore 0511//Singapore/; Merck KGaA,Darmstadt//Germany/; Univ Hosp Gasthuisberg,B-3000 Louvain//Belgium/
Journal: JOURNAL OF CLINICAL ONCOLOGY , 2006 , V 24 , N18,1,S (JUN 20) , P 159S-159S
ISSN: 0732-183X Publication date: 20060620
Publisher: AMER SOC CLINICAL ONCOLOGY , 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA

22314 USA

Language: English Document Type: MEETING ABSTRACT

2/3/13 (Item 1 from file: 73)

Fulltext available through: [STIC Full Text Retrieval Options](#)

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

0082294167 EMBASE No: 2008118672

Cetuximab cuts progression risk by 15% in CRYSTAL trial: Commentary

Lichtman S.M. // Lichtman S.M.

Clinical Geriatrics Program, Memorial Sloan-Kettering Cancer Center, Commack, NY, United States // Clinical Geriatrics Program, Memorial Sloan-Kettering Cancer Center, New York City, NY, United States

Corresp. Author: Lichtman S.M.

Corresp. Author Affil: Clinical Geriatrics Program, Memorial Sloan-Kettering Cancer Center, Commack, NY, United States

Oncology Report (Oncol. Rep.) (United States) September 1, 2007 , -/FALL (35-36)

ISSN: 15485323 eISSN: 15485323

Document Type: Journal ; Short Survey Record Type: Citation

Language: English

2/3/14 (Item 2 from file: 73)

Fulltext available through: [STIC Full Text Retrieval Options](#)

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

0081449792 EMBASE No: 2006512877

Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer

Hopfner M.; Sutter A.P.; Huether A.; Baradari V. // Scherubl H.

Charite-Universitätsmedizin Berlin, Medical Clinic I, Department of Gastroenterology/Infectious Diseases/Rheumatology, Campus Benjamin Franklin, Berlin, Germany // Klinik für Gastroenterologie und Gastrointestinale Onkologie, Vivantes-Klinikum Am Urban, Dieffenbachstr. 1, Berlin 10967, Germany

Author email: hans.scherubl@vivantes.de

Corresp. Author: Scherubl H.

Corresp. Author Affil: Klinik für Gastroenterologie und Gastrointestinale Onkologie, Vivantes-Klinikum Am Urban, Dieffenbachstr. 1, Berlin 10967, Germany

Corresp. Author email: hans.scherubl@vivantes.de

World Journal of Gastroenterology (World J. Gastroenterol.) (China) September 21, 2006 , 12/35 (5635-5643)

CODEN: WJGAF ISSN: 10079327

Document Type: Journal ; Article Record Type: Abstract

Language: English Summary language: English

Number of References: 45

2/3/15 (Item 1 from file: 135)
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000797153 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers from University of Pennsylvania, Department of Physiology provide details of new studies and findings in the area of monoclonal antibodies

Biotech Business Week, April 21, 2008, p.1872

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
276

2/3/16 (Item 2 from file: 135)
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000780523 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Studies from University of Pennsylvania, Department of Physiology describe new findings in life sciences

Biotech Business Week, March 31, 2008, p.1694

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
297

2/3/17 (Item 3 from file: 135)
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000739973 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Study data from University Francois Rabelais of Tours provide new insights into monoclonal antibodies

Biotech Business Week, February 4, 2008, p.1757

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
345

2/3/18 (Item 4 from file: 135)
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000722183 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Yale University details research in colon cancer

Biotech Business Week, January 14, 2008, p.448

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
432

2/3/19 (Item 5 from file: 135)
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000436950 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Merck KgaA reports Erbitux meets primary endpoint in metastatic colorectal cancer study

Biotech Business Week, February 5, 2007, p.216

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
201

2/3/20 (Item 6 from file: 135)
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000375801 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Merck KgaA reports survival data from Erbitux studies in metastatic colorectal cancer

Cancer Weekly, December 5, 2006, p.79

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
368

2/3/21 (Item 7 from file: 135)

NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000317283 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Merck KGaA releases new Erbitux data

Biotech Business Week, July 10, 2006, p.84

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
538

2/3/22 (Item 8 from file: 135)
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000315390 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Clinical data suggest Erbitux recruits immune system to help fight cancer

Biotech Business Week, July 3, 2006, p.73

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
965

2/3/23 (Item 9 from file: 135)
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000284797 (USE FORMAT 7 OR 9 FOR FULLTEXT)

ImClone completes enrollment in studies of Erbitux in three cancer types

Biotech Business Week, March 13, 2006, p.88

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
569

2/3/24 (Item 10 from file: 135)

NewsRx Weekly Reports

(c) 2008 NewsRx. All rights reserved.

0000212543 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers determine structure of binding site of drug and its protein target

Cancer Weekly, May 10, 2005, p.153

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
476

2/3/25 (Item 11 from file: 135)

NewsRx Weekly Reports

(c) 2008 NewsRx. All rights reserved.

0000206832 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Pharma company announces financial results with tripled profit after tax gains

Biotech Business Week, April 11, 2005, p.217

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:

826

2/3/26 (Item 12 from file: 135)

NewsRx Weekly Reports

(c) 2008 NewsRx. All rights reserved.

0000174596 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Pharma company announces profit increase of 43%

Biotech Business Week, November 22, 2004, p.60

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:

651

2/3/27 (Item 13 from file: 135)

NewsRx Weekly Reports

(c) 2008 NewsRx. All rights reserved.

0000155605 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Pharmaceutical company announces second quarter financial results

Biotech Business Week, August 23, 2004, p.215

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
755

2/3/28 (Item 1 from file: 144)

Pascal

(c) 2008 INIST/CNRS. All rights reserved.

18436599 PASCAL No.: 08-0007200

Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment : Antibodies in cancer treatment-II

MAGDELAINE -BEUZELIN Charlotte; KAAS Quentin; WEHBI Vanessa;
OHRESSER Marc; JEFFERIS Roy; LEFRANC Marie-Paule; WATIER Herve
Universite Francois Rabelais de Tours, EA 3853 Immuno -Pharmaco
-Genetique des Anticorps therapeutiques, France; CHRU de Tours, Laboratoire
d'Immunologie, France; JMGT, Laboratoire d'ImmunoGenetique Moleculaire,
LIGM, Institut de Genetique Humaine, UPR CNRS 1142, Montpellier, France;
Immunity and Infection, University of Birmingham, United Kingdom
GPO (Groupe de Pharmacologie Clinique Oncologique. Congress (FRA)
Journal: Critical reviews in oncology/hematology
, 2007, 64 (3
) 210-225
Language: English

Copyright (c) 2008 INIST-CNRS. All rights reserved.

2/3/29 (Item 1 from file: 357)

Derwent Biotech Res.

(c) 2008 The Thomson Corp. All rights reserved.

0391465 DBA Accession No.: 2006-04961 PATENT

New crystal of epidermal growth factor receptor extracellular domain and cetuximab Fab, useful for treating tumor or hyperproliferative disease, e.g. psoriasis using bioinformatics for crystal protein structure analysis for use in cancer therapy

Author: KUSSIE P H; FERGUSON K M

Patent Assignee: UNIV PENNSYLVANIA; IMCLONE SYSETMS INC 2006

Patent Number: WO 200609694 Patent Date: 20060126 WPI Accession No.: 2006-110508 (200611)

Priority Application Number: US 634363 Application Date: 20041208

National Application Number: WO 2005US20969 Application Date: 20050614
Language: English

2/3/30 (Item 1 from file: 149)

TGG Health&Wellness DB(SM)

(c) 2008 The Gale Group. All rights reserved.

03693426 Supplier Number: 179596338 (USE FORMAT 7 OR 9 FOR FULL TEXT)

New Analyses of Pivotal Phase 3 Study of ERBITUX(R) Demonstrate Enhanced Efficacy in First-Line Metastatic Colorectal Cancer Patients with Wild-Type K-Ras Biomarker.

Business Wire , NA

June 1 ,

2008

Publication Format: Newswire

Language: English

Record Type: Fulltext Target Audience: Trade

Word Count: 2323 Line Count: 00204

Company Names: ImClone Systems Inc.; Merck KGAA

Descriptors: Metastasis--Care and treatment; Cancer patients--Care and treatment; Colorectal cancer--Care and treatment; Cancer--Care and treatment; Cancer-- Research; Diagnostic reagents industry; Chemical industry; Herbicides; Pesticides industry; Antimitotic agents; Antineoplastic agents; Oncology, Experimental

Product/Brand Names: Erbitux (Medication)

SIC Codes: 2835 Diagnostic substances; 2819 Industrial inorganic chemicals, not elsewhere classified; 2869 Industrial organic chemicals, not elsewhere classified; 2899 Chemical preparations, not elsewhere classified; 2834 Pharmaceutical preparations; 8000 HEALTH SERVICES; 8730 Research and Testing Services

Product/Industry Names: 2834140 (Anticancer Drugs); 2834146 (Chemotherapeutic Drugs); 8000432 (Cancer Therapy); 8000220 (Cancer & Cell R&D)

NAICS Codes: 325412 Pharmaceutical Preparation Manufacturing; 621 Ambulatory Health Care Services; 54171 Research and Development in the Physical, Engineering, and Life Sciences

Ticker Symbols: IMCL

File Segment: NW File 649

2/3/31 (Item 2 from file: 149)

TGG Health&Wellness DB(SM)

(c) 2008 The Gale Group. All rights reserved.

03593027 Supplier Number: 176203382 (USE FORMAT 7 OR 9 FOR FULL TEXT)

Targeted therapies: a new generation of cancer treatments.(Clinical report)

Gerber, David E.

American Family Physician , 77 , 3 , 311

Feb 1 ,

2008

Document Type: Clinical report Publication Format: Magazine/Journal

ISSN: 0002-838X

Language: English

Record Type: Fulltext Target Audience: Professional

Word Count: 4561 Line Count: 00592

Descriptors: Drug targeting--Methods; Drug targeting--Usage; Monoclonal antibodies-- Dosage and administration; Cancer--Care and treatment; Cancer--Methods

Geographic Codes/Names: 1USA United States

SIC Codes: 8000 HEALTH SERVICES

Product/Industry Names: 8000432 (Cancer Therapy)

NAICS Codes: 621 Ambulatory Health Care Services

File Segment: HI File 149

2/3/32 (Item 3 from file: 149)

TGG Health&Wellness DB(SM)

(c) 2008 The Gale Group. All rights reserved.

03566839 Supplier Number: 174840226 (USE FORMAT 7 OR 9 FOR FULL TEXT)

Structural Basis for EGF Receptor Inhibition by the Therapeutic Antibody IMC-11F8.(Author abstract)(Report)

Li, Shiqing; Kussie, Paul; Ferguson, Kathryn M.

Structure , 16 , 2 , 216(12)

Feb 12 ,

2008

Document Type: Report; Author abstract Publication Format: Magazine/Journal

ISSN: 0969-2126

Language: English

Record Type: Abstract Target Audience: Academic

Descriptors: Biopharmaceutics--Physiological aspects; Biopharmaceutics--Health aspects; Antibodies--Physiological aspects; Antibodies--Health aspects; Viral antibodies--Physiological aspects; Viral antibodies--Health aspects; Epidermal growth factor--Physiological aspects; Epidermal growth factor-- Health aspects

2/3/33 (Item 4 from file: 149)

TGG Health&Wellness DB(SM)

(c) 2008 The Gale Group. All rights reserved.

03285707 Supplier Number: 164531313 (USE FORMAT 7 OR 9 FOR FULL TEXT)

Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting.

Business Wire , NA

June 5 ,

2007

Publication Format: Newswire

Language: English

Record Type: Fulltext Target Audience: Trade

Word Count: 2911 Line Count: 00256

Company Names: ImClone Systems Inc.--Conferences, meetings and seminars
Descriptors: Diagnostic reagents industry--Conferences, meetings and seminars; Antimitotic agents--Conferences, meetings and seminars; Antineoplastic agents--Conferences, meetings and seminars; Metastasis--Conferences, meetings and seminars; Colorectal cancer--Conferences, meetings and seminars; Patients--Care and treatment; Patients--Conferences, meetings and seminars; Cancer--Care and treatment; Cancer--Conferences, meetings and seminars

Product/Brand Names: Erbitux (Medication)

SIC Codes: 2835 Diagnostic substances; 2834 Pharmaceutical preparations; 8000 HEALTH SERVICES

Product/Industry Names: 2834140 (Anticancer Drugs); 2834146 (Chemotherapeutic Drugs); 8000432 (Cancer Therapy)

NAICS Codes: 325412 Pharmaceutical Preparation Manufacturing; 621 Ambulatory Health Care Services

Ticker Symbols: IMCL

File Segment: NW File 649

2/3/34 (Item 5 from file: 149)

TGG Health&Wellness DB(SM)

(c) 2008 The Gale Group. All rights reserved.

03280154 Supplier Number: 164330452 (USE FORMAT 7 OR 9 FOR FULL TEXT)

ImClone Systems to Host Investor Reception on June 5, 2007 Following a Clinical Science Symposium Session about EGFR as a Therapeutic Target in GI Malignancy.

Business Wire , NA

June 1 ,

2007

Publication Format: Newswire

Language: English

Record Type: Fulltext Target Audience: Trade

Word Count: 1903 Line Count: 00168

Company Names: ImClone Systems Inc.

Descriptors: Diagnostic reagents industry--Health aspects; Antimitotic agents--Health aspects; Antineoplastic agents--Health aspects; Cancer--Care and treatment; Cancer--Health aspects

Product/Brand Names: Erbitux (Medication)-Health aspects

SIC Codes: 2835 Diagnostic substances; 2834 Pharmaceutical preparations; 8000 HEALTH SERVICES

Product/Industry Names: 2834140 (Anticancer Drugs); 2834146 (Chemotherapeutic Drugs); 8000432 (Cancer Therapy)

NAICS Codes: 325412 Pharmaceutical Preparation Manufacturing; 621 Ambulatory Health Care Services

Ticker Symbols: IMCL

File Segment: NW File 649

2/3/35 (Item 6 from file: 149)

TGG Health&Wellness DB(SM)

(c) 2008 The Gale Group. All rights reserved.

02759598 Supplier Number: 142157185 (USE FORMAT 7 OR 9 FOR FULL TEXT)

ImClone Systems Announces Complete Enrollment of Several Studies Examining Potential Survival Benefit Of ERBITUX(R) In Three Major Cancer Types.

Business Wire , NA

Feb 16 ,

2006

Publication Format: Newswire

Language: English

Record Type: Fulltext Target Audience: Trade

Word Count: 1523 Line Count: 00135

Company Names: ImClone Systems Inc.; Merck KGAA

Descriptors: Cancer--Research; Cancer--Chemotherapy; Diagnostic reagents industry; Chemical industry; Herbicides; Pesticides industry; Oncology, Experimental; Clinical trials; Chemotherapy; Metastasis; Colorectal cancer; Antimitotic agents; Antineoplastic agents

Geographic Codes/Names: 1USA United States; 4EUGE Germany

SIC Codes: 2835 Diagnostic substances; 2800 CHEMICALS AND ALLIED PRODUCTS; 8730 Research and Testing Services; 2834 Pharmaceutical preparations

Product/Industry Names: 8000220 (Cancer & Cell R&D); 2834140 (Anticancer Drugs); 2834146 (Chemotherapeutic Drugs)

NAICS Codes: 54171 Research and Development in the Physical, Engineering, and Life Sciences; 325412 Pharmaceutical Preparation Manufacturing

Ticker Symbols: IMCL

File Segment: NW File 649

2/3/36 (Item 1 from file: 266)

FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rights reserved.

00605457

Identifying No.: 5R01CA090466-06 Agency Code: CRISP

Structural Studies of Growth Factor Receptor Function

Principal Investigator: LEAHY, DANIEL J

Address: dleahy@bs.jhmi.edu JOHNS HOPKINS UNIVERSITY 725 N WOLFE STREET BALTIMORE, MD 21205

Performing Org.: JOHNS HOPKINS UNIVERSITY , BALTIMORE , MARYLAND

Sponsoring Org.: NATIONAL CANCER INSTITUTE

Dates: 2004/01/01 To 2007/31/11 Fy : 2007

2/3/37 (Item 1 from file: 399)

CA SEARCH(R)

(c) 2008 American Chemical Society. All rights reserved.

144164224 CA: 144(10)164224u PATENT

Co-crystal structure of epidermal growth factor receptor extracellular domain and cetuximab Fab fragment
its use in screening for mimetics for treatment of tumors and psoriasis

Inventor (Author): Kussie, Paul H.; Ferguson, Kathryn M.

Location: USA

Assignee: Imclone Systems Incorporated; The University of Pennsylvania

Patent: PCT International ; WO 200609694 A2 Date: 20060126

Application: WO 2005US20969 (20050614) *US 2004PV579843 (20040614) *US 2004PV634363 (20041208)

Pages: 169 pp.

CODEN: PIXXD2

Language: English

Patent Classifications:

Class: C07K-014/71A

Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR;
CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG;
KM; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ;
OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ;
VC; VN; YU; ZA; ZM; ZW

Designated Regional: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; MC;
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW;
GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

2/3/38 (Item 1 from file: 444)

New England Journal of Med.

(c) 2008 Mass. Med. Soc. All rights reserved.

00130113

Copyright 2008 by the Massachusetts Medical Society

Drug Therapy: EGFR Antagonists in Cancer Treatment (Review Article)

Ciardiello, Fortunato; Tortora, Giampaolo.

The New England Journal of Medicine

Mar 13 , 2008 ; 358 (11),pp 1160-1174

Line Count: 00623 Word Count: 08603

2/3/39 (Item 2 from file: 444)

New England Journal of Med.

(c) 2008 Mass. Med. Soc. All rights reserved.

00129668

Copyright 2007 by the Massachusetts Medical Society

Cetuximab for the Treatment of Colorectal Cancer (Original Articles)

Jonker, Derek J.; O'Callaghan, Chris J.; Karapetis, Christos S.; Zalcberg, John R.; Tu, Dongsheng; Au, Heather-Jane; Berry, Scott R.; Krahn, Marianne; Price, Timothy; Simes, R. John; Tebbutt, Niall C.; van Hazel, Guy; Wierzbicki, Rafal; Langer, Christiane; Moore, Malcolm J.

The New England Journal of Medicine

Nov 15, 2007 ; 357 (20), pp 2040-2048

Line Count: 00466 Word Count: 06432

? d s

Set Items Description

S1 69 S (CETUXIMAB OR ERBITUX OR MABC225 OR IMC-C225) (N50) (CRYSTAL? OR CO-CRYSTAL? OR COCRYSTAL?)

S2 39 RD (unique items)

S3 0 S S2 AND PY<=2003

S4 0 S S2 AND PY<=2003

? S ((Mab h425) or (EMD 72000)) (N50) (CRYSTAL? OR CO-CRYSTAL? OR COCRYSTAL?)

0 MAB H425

294 EMD 72000

4187178 CRYSTAL?

592 CO-CRYSTAL?

8935 COCRYSTAL?

S5 0 S ((MAB H425) OR (EMD 72000)) (N50) (CRYSTAL? OR CO-CRYSTAL? OR COCRYSTAL?)

? S (EGFR antibody) (N50) (CRYSTAL? OR CO-CRYSTAL? OR COCRYSTAL?)

9 EGFR ANTIBODY

4187178 CRYSTAL?

592 CO-CRYSTAL?

8935 COCRYSTAL?

S6 0 S (EGFR ANTIBODY) (N50) (CRYSTAL? OR CO-CRYSTAL? OR COCRYSTAL?)

?

? S (anti-EGFR antibody) (N50) (CRYSTAL? OR CO-CRYSTAL? OR COCRYSTAL?)

25 ANTI-EGFR ANTIBODY

4187178 CRYSTAL?

592 CO-CRYSTAL?

8935 COCRYSTAL?

S7 0 S (ANTI-EGFR ANTIBODY) (N50) (CRYSTAL? OR CO-CRYSTAL? OR COCRYSTAL?)

?